News/ News/ Oncology ASCO21: Novartis’ prostate cancer radiotherapy extends survival Phil Taylor 177Lu-PSMA-617, ASCO 2021, Novartis, Oncology, Prostate cancer, Radiopharmaceutical 0 Comment Novartis’ big investment in radiopharmaceuticals for cancer seems to have paid off, after lead candidate 177Lu-PSMA-617 helped men Share X ASCO21: Novartis’ prostate cancer radiotherapy extends survival https://pharmaphorum.com/news/asco21-novartis-prostate-cancer-radiotherapy-extends-survival/